Radium-223 dichloride (Xofigo, BAY88-8223)

Phase 3

BAYER (BAYRY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Prostatic Neoplasms

Clinical Trial

NCT01934790

Last updated: 12/30/2025

Regulatory Approvals

EMA11/13/2013

Xofigo

Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

View on EMA

Developer

BAYRY

BAYER

Healthcare•North America•NASDAQ

Related Pipeline

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

EE20/DRSP (YAZ, BAY86-5300)Phase 3

Oral Contraceptive

View full pipeline